Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms
Description of Invention:
This technology identifies twenty five (25) new alternatively spliced transcripts of the BORIS gene. The transcripts lead to the expression of seventeen different protein isoforms with variable N- and C-termini encoded by BORIS gene locus. Differential expression levels of BORIS isoforms were observed in different cancers. While some BORIS alternative splice variants were expressed at different levels in all types of cancers, other expressed forms are specific to particular cancer(s).
Advantages and Applications:
Simple, rapid, RT-PCR based diagnostic test to detect BORIS isoforms in cancer patients.
Profiling of BORIS splice variants can be useful as a diagnostic tool for the detection of cancers.
BORIS can be a therapeutic target antigen for immunotherapeutic and/or siRNA based treatments for cancer.
BORIS can be used in combination with other established immunogens for immunotherapeutic treatment of several cancers.
Market:
Approximately 600,000 deaths from cancer related diseases are estimated in 2007. The technology, involving a differential expression of BORIS isoforms in cancer, can be useful for the diagnostics and treatment of several cancers having a potential market of more than 7 billion U.S. dollars.
Development Status:
The technology is currently in the pre-clinical stage of development.
Patent Status:
DHHS Reference No. E-117-2006/0 --
U.S. Provisional Application No. 60/841,342 filed 31 Aug 2006
Licensing Status: Available for exclusive and non-exclusive licensing.
Collaborative Research Opportunity:
The NIAID Laboratory of Immunopathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize methods of cancer diagnostics and treatment based on detection of BORIS isoforms. Please contact Cecilia Pazman at pazmance@niaid.nih.gov or (301) 451-3526 for more information.
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-DNA Based Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: Mojdeh Bahar J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-2950
Email: baharm@mail.nih.gov
Fax: (301) 402-0220
